Zonisamide to label warning letters due to side effects.

Published: 2002-09-18 06:57:00

Updated: 2002-09-18 06:57:00

The KFDA instructed all physicians and pharmacists on Sept. 16 carefully to monitor the hypohidrosis and rise of body temperatures for the patients, especially children who were medicated with Zonisamide, an anti-epileptic agent, until they receive further notification from the KFDA.

The KFDA...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK